Whatever kind of MS you have, there are treatment options that you can discuss with your MS team. Treatments include medication and other therapies.

Many women with multiple sclerosis are menopausal or perimenopausal, but the impact of menopause on MS is not fully understood as there has been limited research published in this area.

The MS Trust is working with MS nurses on a competency framework for MS specialist nurses to create a resource for use by MS nurse team leads, managers and nurses.

Compare the different types of disease modifying drugs (DMDs) that are available to treat multiple sclerosis (MS).

Briumvi (ublituximab) is a disease modifying drug for active relapsing remitting multiple sclerosis (MS). It is taken as an infusion.

Kesimpta (ofatumumab) is a disease modifying drug treatment for relapsing remitting MS. You take Kesimpta as an injection under the skin once a month.

Vumerity (diroximel fumarate) is a disease modifying drug licenced for relapsing remitting multiple sclerosis (MS).  It is taken as two tablets, twice a day.

The immune system is the body's main defence system against infections or foreign substances. It is involved in nerve damage in MS, and is a key area for research into new MS treatments.

Clinically isolated syndrome (CIS) is a first episode of neurological symptoms lasting at least 24 hours. Although some people never go on to experience further neurological symptoms, in others CIS can be the first sign of what may later turn out to be multiple sclerosis.